Limits...
A review of psoriasis, a known risk factor for cardiovascular disease and its impact on folate and homocysteine metabolism.

McDonald I, Connolly M, Tobin AM - J Nutr Metab (2012)

Bottom Line: Psoriasis is a chronic inflammatory skin condition with an increased risk of cardiovascular disease.This risk has been attributed to an association with many independent risk factors including obesity, hypertension, smoking, and dyslipidemia.It has been postulated that low folate levels in this group may be a direct cause of hyperhomocysteinemia and therefore a treatable risk factor by folate supplementation.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology, The Adelaide and Meath Hospital Incorporating the National Children's Hospital, Tallaght, Dublin 24, Ireland.

ABSTRACT
Psoriasis is a chronic inflammatory skin condition with an increased risk of cardiovascular disease. This risk has been attributed to an association with many independent risk factors including obesity, hypertension, smoking, and dyslipidemia. Psoriasis patients also have lower levels of folate and conversely higher levels of homocysteine, which in itself is a risk factor for cardiovascular disease. It has been postulated that low folate levels in this group may be a direct cause of hyperhomocysteinemia and therefore a treatable risk factor by folate supplementation. This paper looks at the literature published to date on the relationship between psoriasis, homocysteine, and folate levels.

No MeSH data available.


Related in: MedlinePlus

Proposed action of combination therapy, in addition to risk factors such as age, sex, hypertension, and dyslipidemia, homocysteine and inflammation lead to increased incidence of vascular disease. Consequently reducing inflammation with methotrexate and hyperhomocysteinemia by folic acid may lead to a decreased incidence of vascular disease for patients with psoriasis [24].
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3368579&req=5

fig2: Proposed action of combination therapy, in addition to risk factors such as age, sex, hypertension, and dyslipidemia, homocysteine and inflammation lead to increased incidence of vascular disease. Consequently reducing inflammation with methotrexate and hyperhomocysteinemia by folic acid may lead to a decreased incidence of vascular disease for patients with psoriasis [24].

Mentions: The possible benefit of folate supplementation seems logical [22]. Folate has long been used in combination with methotrexate in the management of psoriasis, psoriatic arthritis, and rheumatoid arthritis. Here it is effective in reducing gastrointestinal side effects and liver function test abnormalities [23]. In a retrospective cohort study looking at over seven thousand patients with psoriasis, methotrexate was found to reduce the incidence of vascular disease and this reduction was further enhanced when folic acid was added (Figure 2) [24].


A review of psoriasis, a known risk factor for cardiovascular disease and its impact on folate and homocysteine metabolism.

McDonald I, Connolly M, Tobin AM - J Nutr Metab (2012)

Proposed action of combination therapy, in addition to risk factors such as age, sex, hypertension, and dyslipidemia, homocysteine and inflammation lead to increased incidence of vascular disease. Consequently reducing inflammation with methotrexate and hyperhomocysteinemia by folic acid may lead to a decreased incidence of vascular disease for patients with psoriasis [24].
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3368579&req=5

fig2: Proposed action of combination therapy, in addition to risk factors such as age, sex, hypertension, and dyslipidemia, homocysteine and inflammation lead to increased incidence of vascular disease. Consequently reducing inflammation with methotrexate and hyperhomocysteinemia by folic acid may lead to a decreased incidence of vascular disease for patients with psoriasis [24].
Mentions: The possible benefit of folate supplementation seems logical [22]. Folate has long been used in combination with methotrexate in the management of psoriasis, psoriatic arthritis, and rheumatoid arthritis. Here it is effective in reducing gastrointestinal side effects and liver function test abnormalities [23]. In a retrospective cohort study looking at over seven thousand patients with psoriasis, methotrexate was found to reduce the incidence of vascular disease and this reduction was further enhanced when folic acid was added (Figure 2) [24].

Bottom Line: Psoriasis is a chronic inflammatory skin condition with an increased risk of cardiovascular disease.This risk has been attributed to an association with many independent risk factors including obesity, hypertension, smoking, and dyslipidemia.It has been postulated that low folate levels in this group may be a direct cause of hyperhomocysteinemia and therefore a treatable risk factor by folate supplementation.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology, The Adelaide and Meath Hospital Incorporating the National Children's Hospital, Tallaght, Dublin 24, Ireland.

ABSTRACT
Psoriasis is a chronic inflammatory skin condition with an increased risk of cardiovascular disease. This risk has been attributed to an association with many independent risk factors including obesity, hypertension, smoking, and dyslipidemia. Psoriasis patients also have lower levels of folate and conversely higher levels of homocysteine, which in itself is a risk factor for cardiovascular disease. It has been postulated that low folate levels in this group may be a direct cause of hyperhomocysteinemia and therefore a treatable risk factor by folate supplementation. This paper looks at the literature published to date on the relationship between psoriasis, homocysteine, and folate levels.

No MeSH data available.


Related in: MedlinePlus